Latest News and Press Releases

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December...

Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million Publication of Seminal Clinical Validation Study Related to Thyroid Products ...

 Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...

Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...

Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...

Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the...

PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The...

In-Network Access for Thyroid Assays for More than 5 Million Members PARSIPPANY, NJ, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it...

PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming...

Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased Conference Call and...